The finding that the TLR7/8 VLPs are more effective at T cell activation than the TLR9a VLPs in particular is significant, since there are ongoing clinical investigations of this VLP (TLR9a VLPs/Vidutolimod) in the cancer-immunotherapy field due to positive results being obtained when combined with pembrolizumab in a phase 1b trial in anti-PD1-resistant metastatic melanoma patients (NCT02680184, Registration Date: 02/11/2016) [18], and combined with nivolumab in a phase II trial in stage IIIb/c/d melanoma patients with lymph node disease (NCT03618641) [25]. This evidence concerns the gene TLR7 and cancer.